Tirzepatide, the drug in Mounjaro and Zepbound, can make birth control pills less reliable for a while. Both FDA labels tell people who take the pill to switch to a non-oral method, or add a barrier method such as condoms, for 4 weeks after starting and for 4 weeks after each dose increase. Below: the label wording, the study behind it, how long the backup window lasts, and how the Ozempic and Wegovy labels differ.
Everything here comes from the current Zepbound and Mounjaro prescribing information (both revised 08/2026) and the Wegovy and Ozempic labels. Where we do our own arithmetic, we say so.
The warning appears in three places in each label: drug interactions (section 7.2), use in people who could become pregnant (section 8.3), and patient counseling (section 17). The core sentence in the Zepbound label reads:
"Use of ZEPBOUND may reduce the efficacy of oral hormonal contraceptives due to delayed gastric emptying. This delay is largest after the first dose and diminishes over time." (Zepbound label, 8.3)
The label then advises people using oral hormonal contraceptives "to switch to a non-oral contraceptive method, or add a barrier method of contraception for 4 weeks after initiation with ZEPBOUND and for 4 weeks after each dose escalation." The Mounjaro label uses the same wording (Mounjaro label, 7.2 and 8.3).
Section 7.2 of both labels adds one more line that matters a lot in practice: "Hormonal contraceptives that are not administered orally should not be affected." So the warning is about pills you swallow. The labels do not list examples, but non-oral hormonal methods include the patch, the vaginal ring, the shot, the implant and hormonal IUDs.
Tirzepatide slows down how fast food and anything else you swallow leaves your stomach. Doctors call this delayed gastric emptying. A pill has to pass from the stomach into the small intestine before most of it can be absorbed into the blood. If the stomach holds onto it longer, the hormone arrives later and in a smaller rush.
Birth control pills rely on keeping hormone levels in a working range. The label does not say tirzepatide makes the pill fail. It says it "may reduce the efficacy," and it treats that risk as serious enough to recommend a backup.
The label also says this stomach effect is strongest after the first dose and fades over time (Zepbound label, 12.2). That is why the advice is tied to starting and to dose increases rather than lasting the whole time you take the drug. Each step up is, in effect, a new first dose at a higher strength.
Section 12.3 of both tirzepatide labels describes a drug interaction study. People took a combined oral contraceptive (0.035 mg ethinyl estradiol and 0.25 mg norgestimate) along with a single 5 mg dose of tirzepatide. Two measures were reported:
| Hormone measured | Drop in peak (Cmax) | Drop in total exposure (AUC) |
|---|---|---|
| Ethinyl estradiol | 59% | 20% |
| Norgestimate | 66% | 21% |
| Norelgestromin (also measured) | 55% | 23% |
The label also reports that the time to peak (tmax) was delayed by 2.5 to 4.5 hours (Zepbound label, 12.3).
In plain terms: the peaks were cut by more than half, and the total amount absorbed fell by about a fifth. The label does not say how big a drop would make a pill fail.
The same section shows why the window is short. The label pairs this with a test using acetaminophen (Tylenol) to show the stomach effect. The first 5 mg dose of tirzepatide cut the acetaminophen peak by 55% and delayed it by 1 hour. When the test was repeated at week 6 on 15 mg, there was "no meaningful impact" on the peak or its timing (Zepbound label, 12.3). The Mounjaro label reports a 50% drop after the first dose and no meaningful impact at week 4 (Mounjaro label, 12.3). The body adapts, but it takes a few weeks.
The Zepbound label starts everyone at 2.5 mg once weekly for 4 weeks, then 5 mg. After that, the dose may go up in 2.5 mg steps, with at least 4 weeks on each dose, to a maximum of 15 mg (Zepbound label, 2.1 and 2.2). Mounjaro uses the same 2.5 mg start and 2.5 mg steps after at least 4 weeks (Mounjaro label, 2.1).
Here is what the backup rule looks like if someone moved up every 4 weeks all the way to 15 mg. This is our example, not a dosing plan. The label lets a prescriber stop at a lower maintenance dose (5, 10 or 15 mg for weight reduction) or wait longer than 4 weeks between steps.
| Weeks | Weekly dose | Backup needed if on the pill? |
|---|---|---|
| 1 to 4 | 2.5 mg (start) | Yes, 4 weeks after starting |
| 5 to 8 | 5 mg | Yes, 4 weeks after this increase |
| 9 to 12 | 7.5 mg | Yes |
| 13 to 16 | 10 mg | Yes |
| 17 to 20 | 12.5 mg | Yes |
| 21 to 24 | 15 mg | Yes |
| 25 onward | 15 mg (no further increase) | Label window has ended |
The point of the table: if you step up every month, the backup windows join end to end. In this example, that means about 24 weeks, close to six months, of using a second method or a non-oral one. That is our arithmetic from the label's rules.
Some practical questions the label does not answer, so ask your prescriber:
The hardest part is often just remembering when each window ends. In Dose Track you can log each dose with its strength, so the date of every increase is on record, and set a reminder for four weeks after it. If nausea or vomiting shows up after a step up, you can log that too and show your prescriber.
The two tirzepatide labels are written for different uses, and their pregnancy sections read differently.
The Zepbound label, for weight loss, says: "Weight loss offers no benefit to a pregnant patient and may cause fetal harm. Advise pregnant patients that weight loss is not recommended during pregnancy and to discontinue ZEPBOUND when a pregnancy is recognized." It adds that human data are too limited to judge the risk of birth defects or miscarriage, and that animal studies suggest possible risk to the fetus (Zepbound label, 8.1). There is a pregnancy exposure registry; the label lists the number 1-844-524-0039.
The Mounjaro label, for type 2 diabetes, says it "should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus," and notes the risks of poorly controlled diabetes during pregnancy (Mounjaro label, 8.1).
The animal findings are similar in both labels. In rats, fetal growth reductions and fetal abnormalities happened at exposures similar to human doses. In rabbits, fetal growth was reduced. The labels note these effects came along with lower weight and food intake in the mother animals.
Neither tirzepatide label gives a set time to stop before trying to conceive. If you are planning a pregnancy, raise it with your prescriber early. Tirzepatide has a half-life of about 5 days, so it takes a few weeks to clear. Our tirzepatide clearance guide walks through that timing.
Both tirzepatide labels describe a small study. Eleven healthy breastfeeding women took a single 5 mg dose. Tirzepatide was undetectable in 164 of 171 milk samples. The total amount found in the other 7 samples over 28 days was less than 0.02% of the mother's dose. The labels state there are no data on effects on the breastfed infant or on milk production, and leave the decision to the patient and prescriber (Zepbound label, 8.2).
Semaglutide, the drug in Ozempic and Wegovy, also slows stomach emptying. But neither label carries a birth control warning. Instead, they include a stop-before-pregnancy rule.
| Label | Birth control pill advice | Planning a pregnancy |
|---|---|---|
| Zepbound, Mounjaro | Non-oral method or add barrier for 4 weeks after start and each increase | No set stop window stated |
| Wegovy | No specific warning | Stop at least 2 months before |
| Ozempic | No specific warning | Stop at least 2 months before |
The Ozempic label shows the results of its own pill study in a figure in section 12.3. Ethinylestradiol and levonorgestrel, a common pill pairing, were tested alongside semaglutide, and the label marks both "No dose adjustment." The footnote says the contraceptive was "assessed at steady state," meaning after semaglutide levels had built up over weeks (Ozempic label, 12.3). The tirzepatide study, by contrast, gave the pill alongside a first dose, when the stomach effect is at its strongest. The study designs are different, so they do not tell you which drug is "safer" with the pill.
The Wegovy label, which now covers both the injection and a tablet, lists ethinyl estradiol and levonorgestrel among drugs with no clinically significant change in a study run with semaglutide tablets. It still tells you to monitor oral medicines taken with Wegovy (Wegovy label, 7.2 and 12.3).
On pregnancy, the Wegovy label says to "discontinue WEGOVY in patients at least 2 months before they plan to become pregnant to account for the long half-life of semaglutide" (Wegovy label, 8.3). The Ozempic label says the same 2 months, "due to the long washout period for semaglutide" (Ozempic label, 8.3). Semaglutide's half-life is about 1 week, and the Wegovy label says it stays in the blood for about 5 to 7 weeks after the last dose. Like Zepbound, Wegovy says to stop when a pregnancy is recognized if you take it for weight loss (Wegovy label, 8.1).
On breastfeeding, the Wegovy label says breastfeeding is not recommended while taking Wegovy tablets, because the tablet contains an absorption enhancer called SNAC, and SNAC or its breakdown products are present in human milk. For the injection, it says there are no data on semaglutide in human milk (Wegovy label, 8.2). The Ozempic label also reports no human milk data (Ozempic label, 8.2).
If you are switching from semaglutide to tirzepatide, note that the tirzepatide rule is tied to starting tirzepatide, and the label makes no exception for people coming from another GLP-1. Ask your prescriber how it applies to you. Our switching guide covers the dose side of that move.
For more on tirzepatide itself, see the Mounjaro and Zepbound brand guides. Planning a procedure too? Read our sibling post on GLP-1 drugs before surgery and anesthesia, which comes from the same stomach-emptying effect.
This article is general information, not medical advice. Talk to your prescriber before you start, change or stop any medicine or birth control method.